



THE REPUBLIC OF UGANDA

**REPORT OF THE AUDITOR GENERAL ON THE FINANCIAL STATEMENTS OF
THE PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC)
CENTRE ACE II PROJECT FOR THE FINANCIAL YEAR ENDED 30TH JUNE 2022**

**OFFICE OF THE AUDITOR GENERAL
UGANDA**

Table of Contents

Table of Contents.....	2
LIST OF ACRONYMS.....	3
REPORT OF THE AUDITOR GENERAL ON THE FINANCIAL STATEMENTS OF THE PHARM- BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC) CENTRE ACE II PROJECT FOR THE FINANCIAL YEAR ENDED 30 TH JUNE, 2022	4
Opinion	4
Basis for Opinion.....	4
Key Audit Matter	4
• Progress of Project Implementation.....	4
Other Information.....	8
Management Responsibilities for the Financial Statements	8
Auditor's Responsibilities for the Audit of the Financial Statements.....	8
Other Reporting Responsibilities.....	10
Report on the Audit of Compliance with Legislation.....	10
Financial Statements	11

LIST OF ACRONYMS

Acronym	Meaning
GOU	Government of Uganda
ICT	Information & Communication Technology
IESBA	International Ethics Standards Board for Accountants
INTOSAI	International Organization of Supreme Audit Institutions
ISSAIs	International Standards of Supreme Audit Institutions
LGs	Local Governments
MDAs	Ministries, Departments and Agencies
MOFPED	Ministry of Finance, Planning and Economic Development
NTR	Non-Tax Revenue
OAG	Office of the Auditor General
PDO	Project Development Objective
PFMA	Public Finance Management Act, 2015
PFMR	Public Finance Management Regulations, 2016
PHAMBIOTRAC	Pharm-Biotechnology and Traditional Medicine
PPDA	Public Procurement & Disposal of Public Assets
PS/ST	Permanent Secretary/Secretary to the Treasury
TI	Treasury Instructions, 2017
UCF	Uganda Consolidated Fund
UGX	Uganda Shilling
USD	United States Dollar

**REPORT OF THE AUDITOR GENERAL ON THE FINANCIAL STATEMENTS OF THE
PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE (PHARMBIOTRAC) CENTRE
ACE II PROJECT FOR THE FINANCIAL YEAR ENDED 30TH JUNE, 2022**

THE RT. HON. SPEAKER OF PARLIAMENT

Opinion

I have audited the accompanying financial statements of the Pharm-Biotechnology And Traditional Medicine (Pharmbiotrac) Centre ACE II Project for the financial year ended 30th June 2022 which comprise the Statement of Financial Position as at 30th June 2022, the Statement of Financial Performance, Statement of Changes in Equity and Statement of Cash Flows together with other accompanying statements for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In my opinion, the financial statements of the Pharm-Biotechnology and Traditional Medicine (Pharmbiotrac) Centre Ace II Project for the financial year ended 30th June 2022 are prepared, in all material respects, in accordance with Section 51 of the Public Finance Management Act, 2015 and the Financial Reporting Guide, 2018, the Financing agreement and the World Bank guidelines.

Basis for Opinion

I conducted my audit in accordance with International Standards of Supreme Audit Institutions (ISSAIs). My responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of my report. I am independent of the Project in accordance with the Constitution of the Republic of Uganda, 1995 (as amended), the National Audit Act, 2008, the International Organization of Supreme Audit Institutions (INTOSAI) Code of Ethics, the International Ethics Standards Board for Accountants (IESBA) Code of Ethics for Professional Accountants (Parts A and B) and other independence requirements applicable to performing audits of Financial Statements in Uganda. I have fulfilled my other ethical responsibilities in accordance with the IESBA Code, and in accordance with other ethical requirements applicable to performing audits in Uganda. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Key Audit Matter

Key Audit Matters are those matters that, in my professional judgment, were of most significance in my audit of the financial statements of the current period. These matters were addressed in the context of my audit of the financial statements as a whole, and in forming my opinion thereon, and I do not provide a separate opinion on these matters. I have determined the matters described below to be key audit matters communicated in my report.

- **Progress of Project Implementation**

The Government of Uganda signed an agreement, dated March 17, 2017 with the World Bank through the International Development Association (IDA) for the financing of the Eastern and Southern Africa Higher Education Centres of Excellence Project (ACE II).

MUST is implementing Category 1 of the Project with a total non-Refundable Grant of USD.6,000,000 channelled to the University by Government and also collaborating with Inter-University Council for East Africa (IUCEA) in carrying out Part 2 and 3 of the Project. The table below shows the allocation of project funds;

Item	Amount (USD)	% age share
Learning	2,450,309	40.8
Research	1,050,700	17.5
Academic collaboration	1,009,175	16.8
Industry / sector partnership	695,320	11.6
M&E Administration	794,496	13.2
Total	6,000,000	100.00

Source: Pharmbiotrac IFR Report as at 30th June 2019.

The Project Development Objective (PDO) for the ACE II is to strengthen selected Eastern and Southern African Higher Education Institutions to deliver quality post-graduate education and build collaborative Research capacity in the regional priority areas.

Pharmbiotrac aims to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa. A review of the progress of the project implementation revealed the following anomalies in the table below;

No	Observation	Recommendation										
1.1	<p><u>Low Disbursement rate of Project Funds</u></p> <p>A review of the Funds disbursement schedules revealed that a sum of USD. 290,728 (60.3%) was received in the year under review out of the expected amount of USD. 1,719,039 resulting into a shortfall of USD. 1,428,311. This represents a performance of only 17% of the target.</p> <p>This implies that government is incurring unnecessary commitment charges on Un-Withdrawn Financing Balance (½ of 1% per annum as per the ACE II Financing Agreement 2017). The low disbursement rate slows project progress and may hinder achievement of targeted results.</p> <p>The funds that were not received were meant for the implementation of some of the following activities which were never implemented.</p> <table border="1"> <thead> <tr> <th>Output</th><th>Activities</th><th>Number of Items</th></tr> </thead> <tbody> <tr> <td rowspan="3">5.1 Action Plan for Learning Excellence</td><td>Establishment of learning teams</td><td>2</td></tr> <tr> <td>Curriculum accreditation (Fast Track fees)</td><td>1</td></tr> <tr> <td>Learning materials - Students Hand Books (PHD & Masters)</td><td>1</td></tr> </tbody> </table>	Output	Activities	Number of Items	5.1 Action Plan for Learning Excellence	Establishment of learning teams	2	Curriculum accreditation (Fast Track fees)	1	Learning materials - Students Hand Books (PHD & Masters)	1	<p>I advised the Accounting to fast track the ongoing activities so that the funds can be released timely.</p>
Output	Activities	Number of Items										
5.1 Action Plan for Learning Excellence	Establishment of learning teams	2										
	Curriculum accreditation (Fast Track fees)	1										
	Learning materials - Students Hand Books (PHD & Masters)	1										

	<p>Lecture room upgrade 1</p> <p>Fuel and maintenance 1</p> <p>Bus (fuel and maintenance) 1</p> <p>Management Response</p> <p>The low disbursement is attributed to on-going activities that would enable us generate DLI's for fund release. For example, International accreditation is about to be completed. Verification for DLI are only done once a year, hence delaying release of funds planned for.</p>							
4.1.2	<p>Absorption of funds</p> <p>The Project received USD. 290,728 during the financial year, and it also had balances brought forward of USD. 1,003,605, thus making a total of USD. 1,294,333 available for spending in the year. Out of the available funds, a sum of USD. 1,073,844 was spent, leading to a funds absorption rate 83%. The unspent funds (USD. 220,489) were left on the bank account.</p> <p>The funds that were not absorbed were meant for the following activities which were subsequently not implemented at all.</p> <table> <tr> <th>Output</th> <th>Activities</th> </tr> <tr> <td>5.2 Action Plan for Research Excellence</td> <td>Equipment Insurance Monographs (Product Monographs) Masters Seminars Supervision fee (PhD) Supervision fee field (Masters) (3 days / Semester) Supervision fee (PhD) (3 days/ Semester)</td> </tr> <tr> <td>5.3 ACE Action Plan for Quality Assurance</td> <td>Quality Assurance and M&E Consultancy Tracer Studies</td> </tr> </table> <p>Management Response</p> <p>The matter of Insurance policy of Equipment is at contract committee level for further management.</p> <p>Tracer studies are always done after obtaining graduates. Most of our students have just graduated hence it will be implemented this financial year.</p> <p>The rest of the activities are continuous and are done when there is need.</p>	Output	Activities	5.2 Action Plan for Research Excellence	Equipment Insurance Monographs (Product Monographs) Masters Seminars Supervision fee (PhD) Supervision fee field (Masters) (3 days / Semester) Supervision fee (PhD) (3 days/ Semester)	5.3 ACE Action Plan for Quality Assurance	Quality Assurance and M&E Consultancy Tracer Studies	<p>I advised the Accounting Officer to always ensure that funds are utilized within the financial year for which they were meant.</p>
Output	Activities							
5.2 Action Plan for Research Excellence	Equipment Insurance Monographs (Product Monographs) Masters Seminars Supervision fee (PhD) Supervision fee field (Masters) (3 days / Semester) Supervision fee (PhD) (3 days/ Semester)							
5.3 ACE Action Plan for Quality Assurance	Quality Assurance and M&E Consultancy Tracer Studies							
4.1.3	<p>Implementation of Outputs and Activities-</p> <p>I assessed the implementation of one (1) output that had been fully quantified with a total of six (6) activities worth USD. 52,351 and noted that;</p>	<p>I advised The Accounting Officer to always ensure that activities and outputs</p>						

	<ul style="list-style-type: none"> • In this One (1) output, only two (2) activities were fully implemented. • In this output no activity was partially implemented. • In this output, four (4) activities were not implemented at all. <p>Non-implementation of planned activities implies that the expected services to the beneficiary communities were not attained. For example, the project did not implement the following planned activities despite having received the required funds.</p> <ol style="list-style-type: none"> 1. Community training kits 2. Training Centre (Traditional Medical Practitioners) IIACM 3. Training Centre (Traditional Medical Practitioners) ANAMED 4. Training Centre (Traditional Medical Practitioners) NCRL centre <p><u>Management Response</u> The three mentioned training centres were not implemented because they were not responding and we decided to replace them. The Training Kits will be procured after MoUs have been signed with the new centres.</p>	are implemented as planned.
4.1.4	<p><u>Diversion/Mischarges</u> I noted that funds to the tune of USD. 5,396.68 were irregularly diverted from the activities on which they were budgeted and spent on other activities (in form of excess expenditure) without seeking and obtaining the necessary approvals. This was attributed to budget indiscipline, poor budgeting practices, and failure by the entities to adhere to the financial management controls but in place.</p> <p>Diversion of funds negatively affects the delivery of services and negates the purpose of budgeting.</p> <p><u>Management Response</u> The diversions mentioned are in respect to over expenditures, were mainly as a result of price fluctuation of procurement of Air tickets. This was particularly so because during Budget projections the project team only estimated the number of flights (Scientific conferences, Trainings, Exchanges etc.) that will occur in a given financial year, however, the actual locations are not known at the budgeting Phases. For example, some of the meetings occur within the East African countries and others outside Africa. The procurement of the Tickets is done within the approved procurement procedures of the University.</p>	I advised the Accounting Officer in future to avoid excess expenditure above budget allocations or else seek authorization for spending over the approved budget.

Other Information

The Accounting Officer of the Project is responsible for the other information. The other information comprises the statement of responsibilities of the Accounting Officer and the commentaries by the Head of Accounts and the Accounting Officer, and other supplementary information. The other information does not include the financial statements and my auditors' report thereon. My opinion on the financial statements does not cover the other information and I do not express an audit opinion or any form of assurance conclusion thereon.

In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially consistent with the financial statements or my knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work I have performed, I conclude that there is a material misstatement of this other information; I am required to report that fact. I have nothing to report in this regard.

Management Responsibilities for the Financial Statements

Under Article 164 of the Constitution of the Republic of Uganda, 1995 (as amended) and Section 45 of the Public Finance Management Act, 2015, the Accounting Officer is accountable to Parliament for the funds and resources of the Project.

The Accounting Officer is also responsible for the preparation of financial statements in accordance with the requirements of the Public Finance Management Act, 2015 and for such internal control as management determines necessary to enable the preparation of financial statements that are free from material misstatement whether due to fraud or error.

In preparing the financial statements, the Accounting Officer is responsible for assessing the Project's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the Accounting Officer has a realistic alternative to the contrary.

The Accounting Officer is responsible for overseeing the Project's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

My objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes my opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISSAIs will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably

be expected to influence the economic decisions of users, taken on the basis of these financial statements.

As part of an audit in accordance with ISSAIs, I exercise professional judgement and maintain professional scepticism throughout the audit. I also;

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Project's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Project's ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the Project to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with the Accounting Officer regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

I also provide the Accounting Officer with a statement that I have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on my independence, and where applicable, related safeguards.

From the matters communicated with the Accounting Officer, I determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. I describe these matters in my auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, I determine that a matter should not be communicated in

my report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Reporting Responsibilities

In accordance with Section 19 (1) of the National Audit Act, 2008, I report to you, based on my work described on the audit of Financial Statements, that; except for the matters raised in compliance with legislation section below, and whose effect has been considered in forming my opinion on financial statements, the activities, financial transactions and information reflected in the financial statements that have come to my notice during the audit, are in all material respects, in compliance with the authorities which govern them.

Report on the Audit of Compliance with Legislation

In accordance with Section 19 of the NAA 2008, I have a responsibility to report material findings on the compliance of the Project with specific matters in key legislations. I performed procedures primarily to identify findings but not to gather evidence to express assurance.


There were no material findings in respect of the compliance criteria for the applicable subject matters to be reported.



John F.S. Muwanga
AUDITOR GENERAL

28th December, 2022

Financial Statements



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY

IMPLEMENTING ENTITY	MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY
PROJECT NAME:	PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE(PHARMBIOTRAC)
REPORT:	FINANCIAL REPORT YEAR ENDED 30/06/2022
PERIOD OF REPORT:	PERIOD 1 ST JULY 2021 TO 30 TH JUNE 2022
REPORTING CURRENCY:	UNITED STATES DOLLARS (USD)



Mbarara University of Science and Technology



Contents

1. STATEMENT OF RESPONSIBILITIES OF THE ACCOUNTING OFFICER	3
2. General Information About PHARMBIOTRAC Project.....	4
The Project Development Objective.....	4
Background:	4
Objectives.....	4
Thematic areas of focus of PHARMBIOTRAC:	5
Main focus to achieving the centre's objectives	5
Key academic programs supported by PHARMBIOTRAC	6
Key achievements	6
3. Commentary on the Financial Statements by the Finance Manager	10
4. Statement of Sources and Uses of Funds.....	12
5. Uses of Funds (Breakdown).....	13
6. Statement of Reimbursable Eligible Expenditure Programs (EEPs)	17
7. DLI - ACHIEVED AS AT 30th June 2022.....	18
8. POLICIES AND PROCEDURES.....	19



1. STATEMENT OF RESPONSIBILITIES OF THE ACCOUNTING OFFICER

The Eastern and Southern Africa Higher Education Centres of Excellence project (ACH II) Financing Agreement requires the recipient through MoES to maintain a financial management system in accordance with the provisions of section 4.09 of the General conditions. The recipient shall cause Mbarara University of science and Technology to have their financial statements audited in accordance with the provision of section 4.09(b) of the general conditions,

Management accepts the responsibility for the financial statements, which have been prepared using appropriate accounting policies in conformity with the financing agreement and in the manner required by the World Bank guidelines for financial reporting and auditing of ACE II financed activities. Management also accepts the responsibility for safeguarding the assets of the project against fraud and other irregularities. Management further accepts the responsibility for the maintenance of accounting records which have been used in the preparation of the financial statements as well as adequate systems of internal financial control,

Financial statements have been prepared on cash basis accounting and comply with the generally accepted accounting practice for the public sector.

Nothing has come to the attention of management to indicate that any breakdown in the functioning of these controls resulting in loss of project funds has occurred during the year,

Management accepts the responsibility that the Project funds have been expended in accordance with the intended purposes as specified in the financing Agreement.

MELUKOR BYAMUKANDA 
Accounting Officer (Names & Signature)

Date: 31/10/2022





2. General Information About PHARMBIOTRAC Project

The Eastern and southern Africa Higher Education centres of Excellence (ACE II) project supports the governments of eight participating countries - Ethiopia, Kenya, Malawi, Mozambique, Rwanda, Tanzania, Uganda and Zambia in strengthening the selected ACEs to deliver quality post-graduate education and build collaborative research capacity in the regional priority areas. In Uganda, the project is implemented by the MoES through Makerere University (MUK) with two centers, Uganda Martyrs University (UMU) and Mbarara University of Science and Technology (MUST).

The Project Development Objective

The Project Development Objective (PDO) is 'To strengthen selected Eastern and Southern African higher education institutions to deliver quality post-graduate education and build collaborative research capacity in the region priority areas.'

Background:

The Pharm-Biotechnology and Traditional Medicine Centre (PHARMBIOTRAC) is one of the 24 Eastern and Southern Africa Higher Education Centers of Excellence (ACE II) Program, and established at MUST in 2017 with the financial support from the World bank to a tune of 6 Million USD provided as a loan to the Government of Uganda and to MUST as "Non-Refundable Grant".

PHARMBIOTRAC is established in order to address one of the key development challenges facing Africa, i.e. low life expectancy and productivity compared to in other continents, majorly due to a high burden of both communicable and non-communicable diseases. The centre hopes to achieve this by use of Africa's rich biodiversity that forms the continent's natural wealth through providing a regional platform for innovative drug development, including exploring the use of traditional medicine in the region.

PHARMBIOTRAC provides support to selected highly motivated, research-focused and qualified candidates to pursue their MSc and PhD study programmes aimed at achieving the goal of the centre through the existing academic structures within MUST and departments that offer PHARMBIOTRAC relevant programmes.

The goal of PHARMBIOTRAC is "to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa".

Vision is "to be a leading African Centre of Excellence for training and research in traditional medicine and pharm-biotechnology",

Mission "to contribute to documentation, validation and value chain development of traditional medicine and biotechnology products for use in pharmaceutical and nutraceuticals industries in the region through training, research and community services for sustainable development".


Objectives

The main objective of PHARMBIOTRAC is to build a critical mass of specialized and skilled human resource that can advance traditional medicine and Pharm-Biotechnology for socio-economic development of Africa, and the specific objectives include to;


- strengthen capacity in the region to train highly skilled and specialized professionals in traditional medicine and Bio-pharmaceuticals,

- strengthen capacity in the region to engage in cutting edge research in TM and systems biology for health products development,
- create capacity in collaboration with private sector industry for development, production and commercialization of TM, biopharmaceuticals and nutraceuticals from research outputs,
- advance the practices of TM/TMK and promote domestication and sustainable utilization of medicinal species.

Governance structure of PHARMBIOTRAC



PHARMBIOTRAC Framework



Thematic areas of focus of PHARMBIOTRAC:

- Understanding Traditional Medicine Philosophy of Health and Disease Prevention and Control,
- Traditional/Herbal Medicine Quality and Safety Standards,
- Herbal Medicine Production/Manufacturing and Quality Control Standards,
- Traditional/Herbal Medicine Knowledge and Material Conservation and Propagation - in-situ, ex situ,
- Traditional/Herbal Medicine/ Clinical Validation Protocols and Standards,
- Pharmaco-Biotechnology-Application of Biotechnology to Drug Discovery, and Drug Production,
- Pharmaceutical Business Management/Regulation.

Main focus to achieving the centre's objectives

- PHARMBIOTRAC provides support to selected highly motivated, research-focused and qualified candidates to pursue their MSc and PhD study programmes aimed at achieving the goal of the centre through the existing academic structures within MUST and departments that offer PHARMBIOTRAC relevant programmes,
- Some of the students receive direct scholarships from PHARMBIOTRAC (covering tuition, stipend and research support) while others are either self-sponsored or by their governments/other organizations,



- At least 20% of the total are regional students and at least 20% are female, designed to comply with World Bank Disbursement Linked Indicator/Result (DLI/DLR) requirements,
- A regional platform for innovations and value addition to use of traditional medicine (mainly herbal products) in the region.

Key academic programs supported by PHARMBIOTRAC

A: PhD by Research (thematic areas above) - Duration 3 years (30 students enrolled)

B: Current Masters programs offered (by course work and research) - Duration 2 years

1. Master of Science in Pharmacology (M.Pha)
2. Master of Science in Pharmacy (Clinical Pharmacy) (M.Sc. Clinical. Pharm.)
3. Master of Science in Pharmacognosy and Natural Medicine Science (M.Sc. PNMS)
4. Master of Science in Pharmaceutical Analysis

C: Short Courses - Certificate of Production and Quality Assurance of Herbal Medicine

Key achievements

- Developed three (3) new masters programs and all 3 were accredited by NCHE for National accreditation:
 - Master of Science in Pharmacy (Clinical Pharmacy) (M.Sc. Clinical Pharm.) (totally 44 students enrolled, 17 graduated),
 - Master of Science in Pharmacognosy and Natural Medicine Science (M.Sc. PNMS) (totally 22 students enrolled, 5 graduated),
 - M Sc. Master of Science in Pharmaceutical Analysis and Quality Assurance (MSc. PHAQA)
- Enrolment on other programme supported by PHARMBIOTRAC:
 - Master of Science in Pharmacology (currently 9 students enrolled)
- Attracted 5 scholarships every year for Clinical Pharmacy Masters Program from the Ministry of Health, Government of Uganda,
- PhD by research in PharmBiotechnology & Traditional Medicine (30 students enrolled, 11 graduated),
- MoU's signed 15
- Short term course One (1) (Certificate in Traditional/herbal Medicine) was successfully developed (188 students attended the course)
- At least 30% of the enrolled students are regional students (outside Uganda)
- 849,460 USD external project funds raised
- 2 Traditional Healers Institutions supported (Dr. Sekagya Institute of Traditional Medicine (SITM), Mpigi District, Uganda and Rukararwe Partnership Workshop for Rural Development (RPWRD), Bushenyi District, Uganda)
- 30 Incubatees (Enterprises) under incubation (Cohort 1 and Cohort 2)
- Established the Friends of PHARMBIOTRAC Foundation, in cooperated in Uganda and in the USA, <https://pharmbiotracfoundation.org/>

一、二、三、四、五、六、七、八、九、十、十一、十二、十三、十四、十五、十六、十七、十八、十九、二十、二十一、二十二、二十三、二十四、二十五、二十六、二十七、二十八、二十九、三十、三十一、三十二、三十三、三十四、三十五、三十六、三十七、三十八、三十九、四十、四十一、四十二、四十三、四十四、四十五、四十六、四十七、四十八、四十九、五十、五十一、五十二、五十三、五十四、五十五、五十六、五十七、五十八、五十九、六十、六十一、六十二、六十三、六十四、六十五、六十六、六十七、六十八、六十九、七十、七十一、七十二、七十三、七十四、七十五、七十六、七十七、七十八、七十九、八十、八十一、八十二、八十三、八十四、八十五、八十六、八十七、八十八、八十九、九十、九十一、九十二、九十三、九十四、九十五、九十六、九十七、九十八、九十九、一百

Master Students Enrolment (regional and national)

Intake year	Regional Male	Regional Female	Regional Total	Total Female	Total Male	Total national + regional	Target	Performance %
2017/2018	2	3	5	4	5	9	15	60
2018/2019	1	1	2	10	24	34	15	227
2019/2020	2	3	5	5	10	15	15	100
2020/2021	4	1	5	4	16	20	15	133
2021/2022	0	0	0	0	0	0	0	0
Cumulative	9	8	17	23	55	78	60	130

PhD Students Enrolment

Intake year	Regional Male	Regional Female	Regional Total	Total Male	Total Female	Total national + regional	Target	Performance %
2017/2018	6	2	8	17	8	25	10	250
2018/2019	0	0	0	1	0	1	10	10
2019/2020	1	0	1	1	1	2	10	20
2020/2021	0	0	0	2	0	2	0	0
2021/2022	0	0	0	0	0	0	0	0
Cumulative	7	2	9	21	9	30	30	100

Short Course Enrolment

		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022	
		July-Dec 2017	Jan-Jun 2018	Jul-Dec 2018	Jan-Jun 2019	Jul-Dec 2019	Jan-Jun 2020	Jul-Dec 2020	Jan-Jun 2021	Jul-Dec 2021	Jan-Jun 2022
Short-term courses - Regional (Female)		2	3	5	4	4	0	2	0	0	2
Short-term courses Regional (Male)		11	2	6	2	9	2	1	0	0	0
Short-term courses Regional (Total)		13	5	11	6	13	2	3	0	0	2
Short-term courses (Female)		4	3	11	7	11	0	6	31	3	27
Short-term courses (Male)		33	8	23	7	15	3	9	14	0	44
Short-term courses (Total)	188	37	11	34	14	26	3	15	45	3	71
Target	5000	500	500	500	500	500	500	500	500	500	500
Performance %	4	7	2	7	3	5	1	3	9	1	14

74

74

MOUs on partnerships for collaboration in applied research and training

		2016/2017		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022	
		July-Dec 2016	Jan-Jun 2017	July-Dec 2017	Jan-Jun 2018	Jul-Dec 2018	Jan-Jun 2019	Jul-Dec 2019	Jan-Jun 2020	Jul-Dec 2020	Jan-Jun 2021	Jul-Dec 2021	Jan-Jun 2022
Total MoUs	15	1	3	0	0	4	0	2	0	0	1	1	3
Targets	12	0	0	2	3	2	2	1	0	1	0	1	0
Performance %	125	0	0	0	0	200	0	200	0	0	0	0	0
												4	

Direct Project Beneficiaries (students and staff) - Cumulative

		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022	
		July-Dec 2017	Jan-Jun 2018	Jul-Dec 2018	Jan-Jun 2019	Jul-Dec 2019	Jan-Jun 2020	Jul-Dec 2020	Jan-Jun 2021	Jul-Dec 2021	Jan-Jun 2022
Beneficiaries	Female	16	4	23	8	20	2	10	31	3	34
Beneficiaries	Male	58	15	55	19	41	5	27	14	0	50
Total		435	74	19	78	27	61	7	37	45	87

Faculty and PhD student's exchanges to promote research and teaching (cumulative)

		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022	
		July-Dec 2017	Jan-Jun 2018	Jul-Dec 2018	Jan-Jun 2019	Jul-Dec 2019	Jan-Jun 2020	Jul-Dec 2020	Jan-Jun 2021	Jul-Dec 2021	Jan-Jun 2022
STU+FAC Male	Regional	2	0	6	8	5	1	0	0	1	4
STU+ FAC Female	Regional	0	0	1	2	5	4	0	0	0	2
STU+ FAC Total	Regional	2	0	7	10	10	5	0	0	1	6
STU+FAC Male	ALL	2	7	7	10	12	1	0	0	1	6
STU+ FAC Female	ALL	0	3	2	2	9	3	0	0	3	5
STU+ FAC Total	73	2	10	9	12	21	4	0	0	4	11
Target	40	9	8	9	10	0	4	0	0	0	0
Percentage %	183	22	125	100	120	0	100				

15

Amount of Externally Generated Revenue in USD (cumulative)

Revenue sources (organisation)	Currency	Committed Grant	2016/2017		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022		Actual release	Performance % received
			July-Dec 2016	Jan-Jun 2017	July-Dec 2017	Jan-Jun 2018	July-Dec 2018	Jan-Jun 2019	July-Dec 2019	Jan-Jun 2020	July-Dec 2020	Jan-Jun 2021	July-Dec 2021	Jan-Jun 2022		
ANAMED Germany - Herbal HIV Therapy	USD	150,000			55,724		55,680		58,595						169,999	113
SNV - Herbal Tick remedie research	USD	180,000					2,556				3,262				5,818	3
ACEI Incubator	USD	250,000							250,000						250,000	100
Royal Museum for Central Africa - HARISSA Project	USD	150,000							5,036		14,903	18,000		15,292	53,231	35
RUFORUM RECAP - Incubator Hub	USD	50,000									25,000			25,000	50,000	100
Royal Museum for Central Africa - ATRAP Project	USD	370,000							57,471	11,614	37,112	39,993	60,303	63,439.19	269,932	73
IFS International Foundation For Science	USD	12,000						11,980							11,980	100
MoSTI Uganda - COVID Project	USD	77,000										38,500			38,500	50
Total		1,219,000			55,724		58,236	11,980	371,102	11,614	84,277	96,493	60,303	109,731	849,460	69
Targets		2,200,000	250,000	250,000	250,000	250,000	300,000	300,000	300,000	300,000	-	-	-	-	123,742.19	

Internationally recognized research publications in disciplines supported by PHARMBIOTRAC (Cumulative)

2016/2017		2017/2018		2018/2019		2019/2020		2020/2021		2021/2022		Total	
July-Dec 2016	Jan-Jun 2017	July-Dec 2017	Jan-Jun 2018	July-Dec 2018	Jan-Jun 2019	July-Dec 2019	Jan-Jun 2020	July-Dec 2020	Jan-Jun 2021	July-Dec 2021	Jan-Jun 2022	128	
Reg	Oth	Reg	Oth	Reg	Oth	Reg	Oth	Reg	Oth	Reg	Oth	Reg	Oth
2	2	3	1	0	2	2	3	13	3	8	3	2	1
10	5	10	6	12	7	12	6	11	4	85	43	128	
												33	

No of Publications (current)	128
Target (Total in 5 years)	150
Performance % (current)	85

Major procurements:

- 2 Project Vehicle procured (Bus and station wagon),
- Laboratory / Production equipment procured and installed,
- Laboratory / Biotechnology equipment procured and installed,
- ICT equipment procured and installed (Office and students),
- Office/student furniture procured (chairs, tables, cupboard),
- PHARMBIOTRAC Boardrooms furniture procured and installed,
- PHARMBIOTRAC Video Conferencing equipment procured and installed,
- PHARMBIOTRAC Living Gene Bank (Herbal Harden) secured and fenced

Major Publications of staff and students (Book Chapters and Journal Articles)

- 122 Journal article and 9 book chapters published\





3. Commentary on the Financial Statements by the Finance Manager

1) Presentation currency

There reporting and presentation currency is the United States dollars (USD) in accordance to the donor requirements. Transactions in Uganda shillings have been converted to dollars using the transaction exchange rate at time of transfer. The Exchange rate as at 30th June 2022 was 3729.52

1) Income

Total receipts during the period were USD 126,711 from World Bank IDA funds in accordance to the verification done. Other sources of income were USD 123,725 from ATRAP Project, USD 15,292 from HARISSA project and USD 25,000 from REFORUM. Balance brought forward to the period was USD 1,003,605 providing total financing of USD 1,294,333

2) Expenditure

Expenditure was USD 1,073,844 out of the total financing of USD 1,294,333 which was a performance of 82.97%.

The major categories of expenditure were as follows:

i) 5.1 Action plan for learning excellence

Total expenditure on action plan for learning excellence was USD 222,160 mainly for outputs of stipend and Tuition for 13 PHD Students and 10 MSc students USD 21,486 for 2 traditional Clinics set up and USD 11, 385 For 20 PHD Students for community placement.

ii) 5.2 Action Plan for Research excellence

Total expenditure on this action plan was USD 259,277 in respect to Research support for 14 PhD and 8 MSc students USD71,908, Journal Publications USD 3,475, staff participation in regional and international conferences and attachment to foreign laboratories USD 96,678, Staff research funds USD 35,019, Establishment of the Living Gene Bank and Germplasm Collection Mission (MUST) USD 27,081.

iii) 5.5 Action plan for attracting academic staff and students from the region

Expenditure was USD 52,318 for salaries of two recruited Senior lecturers in Clinical Pharmacy

iv) 5.6 Action plan for National and Regional academic partners

Expenditure was USD 18,845 in respect to 2 visiting faculty members from Kenya, Sudan and Makere to offer Block lectures to Students.

v) 5.8 Action plan for collaboration with international partners

Expenditure was USD 45,722 for one visiting professors from USA to offer expertise in Clinical Pharmacy

vi) 5.9 Action plan for management and Governance

Expenditure was USD 134,032 in respect to payment of salaries for 4 administrative staff, capacity building and meetings.

vii) 5.10 Action plan for sustainable financing

Expenditure was USD 42,655 in respect to payment of salary for the chair innovation and business management, Business Clinic coordination and Branding, products exhibitions and students hand books.



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

I take full responsibility for the completeness and integrity of these Financial Statements.

Dominique Nwusama
Finance Manager [Names & Signature]

31/10/2022
Date



4. Statement of Sources and Uses of Funds

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (126974) PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE (PHARMBIOTRAC) Statement of Sources and Uses of Funds for the annual period ending 30th June 2022		
Sources of Fund	Annual Period ending From 1st July 2021 to 30th June 2022	Cummulative To Date 60 Months
Opening Cash Balance		
Government Funds	-	-
World Bank IDA Funds	766,157	-
Student Fees	-	-
Partnership With SNV	-	-
IFS-Fund	-	-
Others-Hiv Study Project	2,362	-
ATRAP Project	6,549	-
HARISSA Project	12,467	-
IUCEA-Incubation Centre	191,070	-
REFORUM	25,000	-
Total Cash Balance	1,003,605	
Add Receipts		
Government Funds	-	-
World Bank IDA Funds	126,711	4,881,112
Student Fees	-	1,908
Others-HIV Study Project	-	169,999
IUCEA-Incubation Centre	-	250,000
Partnership With SNV	-	5,818
ATRAP Project	123,725	269,915
HARISSA Project	15,292	53,392
IFS-Fund	-	11,980
REFORUM	25,000	50,000
Total Financing	1,294,333	5,694,125
Less: ACE Expenditure as per Project Implementation Plan		
Expenditure Classification 1 PHARMBIOTRAC	781,680	4,773,397
Expenditure Classification 2 (HIV Study)	2,450	168,501
Expenditure Classification 3 Incubation centre	116,403	175,332
Expenditure Classification 4 ATRAP Project	117,630	257,272
Expenditure Classification 5 HARISSA Project	18,480	44,113
Expenditure Classification 6 SNV	-	5,840
Expenditure Classification 7 IFS	-	11,980
REFORUM	37,202	37,202
Total Uses of Funds by Components	1,073,844	5,473,637
Closing Balances	220,489	220,488
Bank of Uganda A/C 003370088400000	6,518	6,518
Balance as per Stanchart Ugx A/C 0102808265800	10,243	10,243
balance as per Stanchart USD A/C 8702808265800	203,727	203,727
Total Closing Cash Balance	220,488	220,488

Prepared by Dominique MUSAHA
Finance and Administration Director

Approved by Melchori Byambuka
Accounting Officer



5. Uses of Funds (Breakdown)

	Expenditure	Annual Period ending From 1st July 2021 to 30th June 2022			Cumulative Totade 60 Months			Explanation of Variance
		Actual	Planned	Variance	Actual	Planned Cumulative For 5 years	Variance	
	Expenditure Classification 1 as per Project Implementation Plan							
6.1	Action Plan for Learning Excellence							
5.1.1	Benchmarking visits (India)	0	0	0	31,788	31,788	0	Activity Completed
	Benchmarking visits (South Africa)	0	0	0	31,088	31,088	0	Activity Completed
5.1.3	Benchmarking visits (USA)	0	0	0	38,740	38,740	0	Activity Completed
5.1.4	Establishment of learning teams	0	803	803	4,197	5,000	803	Activity Completed
5.1.5	Installation of ICT systems for learning	3,638	8,385	4,747	15,024	22,771	7,747	Activity still on going.
5.1.6	Curriculum development (Short courses MSc & PHD)	0	0	0	22,758	22,758	0	Activity Completed
5.1.7	Curriculum accreditation (Fast Track fees)	4,408	19,000	14,592	44,966	59,263	14,298	Activity still on going.
5.1.8	Students Hand Books (PHD & Masters)	0	1,360	1,360	1,321	1,700	379	Activity still on going.
5.1.9	Learning materials (lecturers reference materials, demonstration materials etc.)	10,992	14,000	3,008	25,855	38,656	12,801	The process is still on going.
5.1.10	Upgrading Learning Facilities Pharmacy (production unit)	2,712	22,146	19,434	56,855	70,000	13,145	The process is still on going.
5.1.11	Lecture room upgrade	0	337	337	11,920	12,000	80	Activity still on going.
5.1.12	Digital Library / ICT learning centre / video conferencing facilities/ computer workstations for students	85	4,820	4,735	92,184	98,013	5,830	ICT Equipment for students has been finalised
5.1.13	Standby generator (purchase & installation)	0	0	0	0	0	0	Activity was put on Hold due to availability Of University Generator
5.1.14	Fuel and maintenance	0	3,600	3,600	7,478	12,778	5,300	Expenditure still on going
5.1.15	Chair Learning Excellence coordination	0	660	660	445	1,105	660	Activity still on going.
5.1.16	Advertisment/ assembling of trainers/ recruitment of students for short courses and training	0	2,000	2,000	0	2,000	2,000	Activity Completed
5.1.17	Advertisment/ assembling, recruitment of students for MSc and PhD, and training	0	1,508	1,508	12,992	14,500	1,508	Activity Completed
5.1.18	Facilitation for industry experts / practitioners (10 ppl)	741	13,800	13,059	7,938	28,996	21,058	The activity is still on going
5.1.19	Tuition Fee PhD	77,887	104,354	26,467	287,627	290,000	2,373	Expenditure still on going
5.1.20	Tuition Fee MSc	19,723	105,833	86,109	85,891	172,000	86,109	Expenditure still on going
5.1.21	Traditional Medicine Clinics setup and maintenance	21,486	70,523	49,037	27,322	81,359	54,037	Activity still on going.
5.1.22	Stipend PhD (annually)	42,050	50,000	7,950	527,370	536,654	9,284	Expenditure Still on Going
5.1.23	Stipend MSc (annually)	6,600	8,000	1,400	221,261	219,566	-1,695	Expenditure still on going
5.1.24	Travel (Flights) for Students (return flights)	732	6,000	5,268	24,323	29,591	5,268	Expenditure still on going
5.1.25	External examiners	0	0	0	0	0	0	Activity Planned for
5.1.26	Annual dissemination conference and Annual general meeting	5,665	29,983	24,318	50,428	74,746	24,318	Activity still on going.
5.1.27	Student presentation at national conferences	0	5,000	5,000	2,011	7,011	5,000	Activity still on going.
5.1.28	Student presentation at regional conferences	0	3,000	3,000	340	3,340	3,000	Activity still on going.
5.1.29	Student presentation at international conferences	0	4,600	4,600	8,701	12,739	4,038	Activity still on going.
5.1.30	Community / Industry attachments (Masters)	5,904	12,918	7,014	38,950	45,964	7,014	Activity still on going.
5.1.31	Community / Industry attachments (PhD)	11,385	13,600	2,215	14,998	15,400	402	Activity still on going.
5.1.32	30 Seater Bus	0	0	0	73,557	73,557	0	Activity Completed
5.1.33	Bus (fuel and maintenance)	8,152	16,618	8,466	11,986	29,271	17,285	Expenditure still on going
5.1.34	Medical emergency fund / First Aid kit	0	1,000	1,000	2,512	5,000	2,488	Expenditure still on going
5.1.35	Students accomodation	0	0	0	12,045	12,045	0	Expendure Closed
	Sub Total	222,160	623,848	301,688	1,794,867	2,099,398	304,531	

Expenditure Classification 2 as per Project Implementation Plan							
5.2	Action Plan for Research Excellence						
5.2.1	Research Policy and Plan draft development (Y1 development Y4 review)	0	0	0	7,974	7,974	0 Expenditure Still on going
5.2.2	Research Policy and Plan finalisation (Y1 development Y4 review)	0	1,828	1,828	0	1,828	1,828 Expenditure Still on going
5.2.3	Staff attachments to foreign laboratories WPI (USA)	7,325	6,530	-795	24,120	23,325	-795 Expenditure Still on going
5.2.4	Staff attachments to foreign laboratories IHST (India)	6,696	8,534	1,838	14,812	16,650	1,838 Expenditure Still on going
5.2.5	Staff attachments to foreign laboratories KEMRI (Kenya)	18,952	17,666	-1,286	25,886	24,600	-1,286 Expenditure Still on going
5.2.6	Staff attachments to foreign laboratories Gezira (Sudan)	13,879	28,150	14,271	13,879	28,150	14,271 Expenditure Still on going
5.2.7	Establishment of Living gene bank (Garden) - MUST	19,848	84,532	64,684	44,748	138,308	93,560 Expenditure Still on going
5.2.8	Staff research funds	35,019	35,019	0	65,000	65,000	0 Expenditure Still on going
5.2.9	Staff participation in regional conference	24,355	25,000	645	56,434	65,079	8,645 Activity still on going
5.2.10	Staff participation in international conference	25,471	25,000	-472	66,679	74,207	7,528 Activity still on going
5.2.11	Germplasm collection missions (MUST)	7,233	31,410	24,177	53,866	80,436	26,570 Activity still on going
5.2.12	Pharm-Biotech laboratory equipment purchase, installation, tear and wear	0	10,000	10,000	94,542	108,280	13,738 Purchase of Lab Equipment was completed
5.2.13	Product development laboratory, purchase, installation, tear and wear	0	15,000	15,000	156,897	186,144	29,247 Purchase of Lab Equipment was completed
5.2.14	Analytical Laboratory, purchase, installation, tear and wear	1,129	6,353	5,224	288,486	293,710	5,224 Purchase of Lab Equipment was completed
5.2.15	Equipment Insurance	0	18,161	18,161		35,691	
5.2.17	Journal Publication fee (Open Access)	3,475	10,000	6,525	10,333	21,858	11,525 Activity still on going
5.2.18	Monographs (Product Monographs)	0	19,620	19,620	0	19,620	19,620 Activity still on going
5.2.19	Masters Seminars	0	2,000	2,000	0	3,000	3,000 Activity still on going
5.2.20	Doctoral Seminars	212	6,000	5,788	3,378	11,495	8,117 Activity still on going
5.2.21	Supervision fee (Masters)	0	0	0	0	0	0 Activity still on going
5.2.22	Supervision fee (PhD)	0	638	638	549	1,546	997 Activity still on going
5.2.23	Supervision fee field (Masters) (3 days / semester)	0	5,823	5,823	178	9,000	8,823 Activity still on going
5.2.24	Supervision fee fee (PhD) (3 days/ semester)	0	2,000	2,000	2,197	3,742	1,545 Activity still on going
5.2.25	Joint follow up proposal development	7,506	31,000	23,494	23,877	54,757	30,880 Activity still on going
5.2.26	Chair Research Excellence coordination	0	663	663	161	824	663 Activity still on going
5.2.27	Research support for MSc students	10,600	32,073	21,473	47,233	84,000	36,767 Activity still on going
5.2.28	Research support for PhD students	61,308	104,482	43,174	346,195	405,000	58,805 Activity still on going
5.2.29	Station wagon purchase (4 wheel drive)	0	0	0	75,993	75,993	0 Activity Completed
5.2.30	Fuel and maintenance for Station wagon (4 wheel drive)	10,275	16,800	6,525	28,146	44,171	16,025 Activity still on going
5.2.31	Laboratory technician	5,993	6,276	283	28,972	32,441	3,468 Activity still on going
Sub Total		269,277	660,656	301,279	1,480,636	1,931,829	416,602
Expenditure Classification 3 as per Project Implementation Plan							
5.3	ACE Action Plan for Quality Assurance						
5.3.1	Quality Assurance and M&E consultancy	213	6,000	5,787	1,088	10,000	8,912 Activity still on going
5.3.2	Chair Learning and Research Quality Assurance	0	0	0	722	722	0 Activity still on going
5.3.3	Tracer studies	713	8,000	7,287	4,273	15,000	10,727 Activity still on going
Sub Total		926	14,000	13,074	6,084	25,722	19,639
Expenditure Classification 4 as per Project Implementation Plan							
5.4	ACE Action Plan regarding Equity Dimensions						
5.4.1	Access audit	0	0	0	0	0	0 Expenditure Put on hold
5.4.2	Facility upgrade	0	0	0	470	470	0 Expenditure Put on hold
Sub Total		0	0	0	470	470	0
Expenditure Classification 5 as per Project Implementation Plan							
5.5	ACE Action Plan for Attracting Academic Staff and Students from the Region						
5.5.1	Dissemination of Research Policy to attract academic staff of the region	0	0	0	0	0	0 Expenditure Put on hold
5.5.2	Language learning support	0	0	0	0	0	0 The activity was dropped. To be implemented by the University for all students
5.5.3	Recruited staff salaries (2 senior lecturers)	52,318	54,913	2,595	264,108	266,770	1,662 Expenditure still on going.
Sub Total		52,318	54,913	2,595	264,108	266,770	1,662

Expenditure Classification 6 as per Project Implementation Plan								
6.6 ACE Action Plan for National and Regional Academic Partners								
5.6.1	Regional Visiting faculty members - Kenya	1,027	12,256	11,229	7,437	18,666	11,229	Activity still on going
5.6.2	Regional Visiting faculty members - South Africa	264	17,684	17,420	5,604	23,025	17,420	Activity still on going
5.6.3	Regional Visiting faculty members - Sudan	11,186	10,000	-1,186	47,385	47,050	-335	Activity still on going
5.6.4	Regional Visiting faculty members - Mozambique	0	0	0	7,687	7,687	0	Activity still on going
5.6.5	National Visiting faculty members - BSU	0	920	920	0	920	920	Activity still on going
5.6.6	National Visiting faculty members - Makerere	4,118	4,506	388	9,842	9,542	-300	Activity still on going
5.6.7	National Visiting faculty members - UTAMU	925	6,520	5,595	925	6,520	5,595	Activity still on going
5.6.8	National Visiting faculty members - Gulu University	0	6,920	6,920	0	6,920	6,920	Activity still on going
5.6.9	Student attachment African Partner - KEMRI - Kenya	188	9,900	9,712	188	9,900	9,712	Activity still on going
5.6.10	Student attachment African Partner - Gezira University - Sudan	0	0	0	0	0	0	Activity still on going
5.6.11	Establishment of Living gene bank (Garden) - BSU/GU	1,137	16,000	14,863	6,137	26,000	19,863	Activity still on going
5.6.12	Germplasm collection maintenance (BSU)	0	15,300	15,300	0	20,300	20,300	
5.6.13	Germplasm collection maintenance (Gulu University)	0	16,695	16,695	8,605	20,300	11,695	Activity still on going
	Sub Total	18,846	116,700	97,866	93,811	196,830	103,018	
Expenditure Classification 7 as per Project Implementation Plan								
6.7 ACE Action Plan for National and Regional Sector Partners								
5.7.1	Community training kits	0	16,950	16,950	11,839	31,500	19,661	Activity Still on going
5.7.2	Training Centre (Traditional Medical Practitioners) BUMETHA	1,280	7,902	6,622	3,978	11,600	7,622	Activity Still on going
5.7.3	Training Centre (Traditional Medical Practitioners) IIACM	0	11,600	11,600	0	11,600	11,600	Activity Still on going
5.7.4	Training Centre (Traditional Medical Practitioners) THETA-Uganda	2,333	3,791	1,458	10,142	11,600	1,458	Activity Still on going
5.7.5	Training Centre (Traditional Medical Practitioners) ANAMED	0	509	509	11,091	11,600	509	Activity Still on going
5.7.6	Training Centre (Traditional Medical Practitioners) NCRL centre	0	11,600	11,600	0	11,600	11,600	Activity Still on going
	Sub Total	3,613	62,351	48,738	37,050	89,600	52,460	Activity Still on going
Expenditure Classification 8 as per Project Implementation Plan								
6.8 ACE Action Plan for Collaboration with International Academic Partners								
5.8.1	International Visiting faculty members (USA)	0	0	0	11,719	11,719	0	Activity still on going
5.8.2	International Visiting faculty members (India)	0	13,132	13,132	4,318	17,450	13,132	Activity still on going
5.8.3	Sabbatical Place (6 months per year)	45,722	44,400	-1,322	144,604	143,643	-961	Activity still on going
	Sub Total	45,722	57,632	11,810	160,642	172,812	12,170	
Expenditure Classification 9 as per Project Implementation Plan								
6.9 ACE Action Plan for Management and Governance								
5.9.1	Establishment of PHARMBIOTRAC secretariat	0	0	0	21,739	21,739	0	Activity was finalised.
5.9.2	Installation of ICT systems for finance & administration	0	0	0	3,375	3,375	0	Activity was finalised.
5.9.3	Inception and planning meeting of all partners	0	0	0	57,089	57,089	0	Activity was finalised.
5.9.4	Meeting of Steering Committee	3,779	20,000	16,221	7,277	35,300	28,023	Activity Still on going
5.9.5	Meeting of Executive Committee	294	1,196	902	5,032	5,700	668	Activity Still on going
5.9.6	Meeting of Finance & Administration committee	1,364	4,000	2,636	8,794	18,430	9,636	Activity Still on going
5.9.7	Core Team Project review and planning meeting	11,548	15,000	3,452	40,986	51,709	10,723	Activity Still on going
5.9.8	PHARMBIOTRAC meetings with WB & IUCEA	1,612	6,814	5,201	10,599	19,600	9,001	Activity still on going.
5.9.9	Bi-Annual Meeting by IUCEA	2,385	26,000	23,615	69,064	101,513	32,448	Activity still on going.
5.9.10	Staff orientation workshop	0	0	0	1,718	1,718	0	Activity was finalised.
5.9.11	PHARMBIOTRAC Administrator	23,998	24,000	2	62,019	72,022	10,003	Activity Still on going
5.9.12	PHARMBIOTRAC Administrative Assistant	5,993	6,000	7	29,472	32,480	3,008	Activity Still on going
5.9.13	PHARMBIOTRAC Accountant	23,998	24,000	2	114,017	126,020	12,003	Activity Still on going
5.9.14	PHARMBIOTRAC Procurement Assistant / Secretary	5,993	6,000	7	28,972	31,981	3,008	Activity Still on going
5.9.15	Partner coordination / supervision visits regional (2 p	532	22,743	22,211	41,029	63,240	22,211	Activity Still on going
5.9.16	Driver	2,996	3,000	4	14,489	15,993	1,504	Activity Still on going
5.9.17	Cleaner	2,389	2,400	11	11,553	12,765	1,212	Activity Still on going
5.9.18	Office supplies	4,263	8,000	3,737	25,006	31,780	6,774	Activity Still on going
5.9.19	Capacity building	33,042	39,029	5,987	120,990	138,978	17,987	Activity Still on going
5.9.20	In land travels	4,264	7,000	2,736	24,699	31,393	6,694	Activity Still on going
5.9.21	Communication	4,743	4,800	57	9,757	12,214	2,457	Activity Still on going
5.9.22	Recruitment of staff	0	500	500	9,433	10,252	819	Activity Still on going
5.9.23	Bank charges	836	500	-336	2,688	2,541	-147	Activity Still on going
5.9.24	Exchange gain/Losses	2	500	498	1,868	3,066	1,198	Exchanges losses recognised as a result of operating different currencies.
	Sub Total	134,032	221,481	87,450	721,665	900,897	179,231	



Pharm-Biotechnology and Traditional Medicine Center (PHARMBIOTRAC)

Expenditure Classification 10 as per Project Implementation Plan							
5.10*	ACE Action Plan for Sustainable Financing						
5.10.1	Chair Innovation & Business Management	29,979	30,000	21	139,867	154,894	15,027
							Expenditure Still on going
5.10.2	Business clinic (furniture, computer, software)	0	0	0	7,422	12,320	4,899
5.10.3	Product exhibitions (Regional)	1,098	13,992	12,894	13,105	26,000	12,894
							Activity is still on going
5.10.4	Product exhibitions (National)	0	6,584	6,584	4,816	11,400	6,584
							Activity is still on going
5.10.5	Chair innovation & Business Management Meetings	432	2,890	2,458	542	3,300	2,758
5.10.6	Student handbooks (in-service professionals short course)	0	4,580	4,580	420	5,000	4,580
							Activity is still on going
5.10.7	Student handbooks (short course for TMPs)	0	6,881	6,881	2,708	9,589	6,881
							Activity is still on going
5.10.8	Business clinic coordination & branding	11,146	18,000	6,854	41,613	58,000	16,387
							Activity is still on going
5.10.9	Subscription to Regional /International bodies eg RUFORUM	0	10,000	0	0	10,000	10,000
							Activity is still on going
	Sub total	42,655	92,927	40,272	210,493	290,502	80,008
Expenditure Classification 11 as per Project Implementation Plan							
5.11	ACE Action Plan for Monitoring and Evaluation						
5.11.1	Strategic plan draft development	0	0	0	0	0	0
							Activity Still on going
5.11.2	Strategic plan finalisation	0	14,732	14,732	1,538	16,270	14,732
							Activity Still on going
5.11.3	M&E Missions (internal)	2,132	10,000	7,868	2,132	10,000	7,868
							Activity Still on going
	Sub Total	2,132	24,732	22,600	3,670	26,270	22,600
	Grand Total Uses of Funds	781,680	1,719,039	927,360	4,773,397	6,000,000	1,180,912

Prepared by Dominique Mursana
Finance and Administration Director

Approved by Melchior Byambura
Accounting Officer





6. Statement of Reimbursable Eligible Expenditure Programs (EEPs)

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY AFRICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (126974) Statement of Reimbursable Eligible Expenditure Programs (EEPs) for the annual period ending 30th June 2022		
Eligible Expenditure Program (EEP)	Annual Period ending 30th June 2022	Cummulative Todate For 60 months
EEP 1: Salaries	10,832,622	53,198,837.68
EEP 2: Non Procurable Expenditure as defined in Financing Agreement	722,818	3,755,661.26
Total EEPs	11,555,440	56,954,499

Note.
Exchange rate used 3729.52

Prepared by Dominique Musana
Finance and Administration Director

Approved by Melchior Nyambura
Accounting Officer






7. DLI - ACHIEVED AS AT 30th June 2022

MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY PHARM-BIOTECHNOLOGY AND TRADITIONAL MEDICINE CENTRE RICA HIGHER EDUCATION CENTERS OF EXCELLENCE PROJECT (1269) DLI - ACHIEVED AS AT 30th June 2022					
DISBURSEMENT LINKED TO INDICATORS	ACTIONS TO BE COMPLETED	AMOUNT ALLOCATED	AMOUNT DISBURSED	Amounts Disbursed after reporting date	UN-DISBURSED BALANCE
DLI1: Institutional readiness	DLR 1.1: To meet Conditions for Effectiveness	600,000	600,000		-
	DLR 1.2: Development of detailed implementation plans	500,000	500,000		-
DLI 2: Excellence in education and research capacity and development impact	DLR 2.1: Timely annual implementation of the plans	-	-		-
	DLR 2.2: Newly enrolled students in the ACE of which at least 20% must be regional (African) students Short Course: Female Ugandans (national)	1,300,000	1,369,000	5,500	(74,500)
	Short Course: Male Ugandan students				-
	Short Course: Female regional (African) students				-
	Short Course: Male regional (African) students				-
	MSc: Female Ugandan students				-
	MSc: Male Ugandan students				-
	MSc: Female regional (African) students				-
	MSc: Male regional (African) students				-
	PhD: Female Ugandan students				-
	PhD: Male Ugandan students				-
	PhD: Female regional (African) students				-
	PhD: Male regional (African) students				-
	DLR 2.3: Accreditation of quality of education programs (program internationally accredited)	600,000	300,000		300,000
	Program regionally accredited				-
	Program nationally accredited				-
	Program for self-evaluation				-
	DLR 2.4: Collaboration and partnerships for applied research and training (MoU with public institutions/civil society)	200,000	100,000		100,000
	MoU with private sector/ industry				-
	DLR 2.5: Peer-reviewed journals papers or peer-reviewed conference papers (paper accepted by a peer reviewed journal)	500,000	500,000		-
	Accepted peer-reviewed conference paper				-
	DLR 2.6: Faculty and PhD student exchanges to promote regional research and teaching ("period" within the country)	700,000	96,000	26,000	578,000
	Exchange "period" within the region				-
	Exchange "period" for international				-
	DLR 2.7: External revenue generation (National level)	900,000	899,400		600
	External revenue generation (International level)				-
	DLR 2.8: Institution participating in benchmarking exercise	100,000	100,000		-
DLI 3: Timely, transparent and institutionally reviewed Financial Management	DLR 3.1: Timely Withdrawal Application supported by financial reporting on the ACE account for the period	75,000	45,000	15,000	15,000
	DLR 3.2: Functioning Audit Committee under the university council	75,000	45,000	15,000	15,000
	DLR 3.3: Functioning internal audit unit for the university	75,000	45,000	15,000	15,000
	DLR 3.4: Transparency of financial management (audit reports, interim financial reports, budgets and annual work plan are all web accessible)	75,000	45,000	15,000	15,000
DLI 4 Timely and audited Procurement	DLR 4.1 Timely procurement audit report	150,000	90,000	-	60,000
	DLR4.2: Timely and satisfactory procurement progress report	150,000	90,000	-	60,000
Total in USD		6,000,000	4,824,400	91,500	1,084,100

Prepared by Dominique Masana
Finance and Administration Director

Approved by Melchor Nyambura
Accounting Officer







8. POLICIES AND PROCEDURES

The Accounting policies and Procedures of Pharm-biotechnology and Traditional Medicine center (PHARMBIOTRAC) are in accordance with the following;

- i) International Financial Reporting Standards,
- ii) The latest issue of the World Bank Financial Accounting Reporting and Audit Guidelines.

2. BASIS OF ACCOUNTING AND REPORTING

- i) The Accounting records and Financial Statements are prepared on a cash basis of accounting (in accordance with the International Public Sector Accounting Standards (IPSAS) issued by International Federation of Accountants (IFAC) and under the historical cost convention.
- ii) Financial transactions are recognized and recorded on cash basis.
- iii) Revenue is recognized when cash is received at the Bank of Uganda (BOU) and Standard Chartered Bank.
- iv) Project expenditures are recognized and recorded when payments are made to beneficiaries and not when the liabilities are created.
- v) Assets are expensed in full in the year of purchase, consistent with the cash basis of Accounting.

3. CURRENCIES

i) Foreign currency transactions

The functional currency for PHARMBIOTRAC is the United States Dollars (US\$), and as much as possible, the records of receipts and payments for the project shall be maintained in US Dollars (US\$), which is the currency of the Grant. In particular transactions on IDA Designated Accounts will be maintained in United States dollars with Bank of Uganda as the Main account. Transactions made from Bank of Uganda to Standard chartered operational accounts are maintained in UGX and US Dollar.

Since the Grant is received in USD dollar, all transactions translated in Ugx shall maintain a same rate at the time of executing the transaction until the funds are fully exhausted of that rate provided by Bank of Uganda.

ii) Local Currency

Where the project recognizes that some of the transactions may be effectively conducted in the local currency i.e. Uganda Shillings, the transaction values shall be translated into Dollars at the respective BOU exchange rates prevailing on the dates of those transactions. The resulting differences from the conversion and translation will be dealt with in the Sources and Uses of funds statement in the year in which they arise.

iii) Exchange differences – gains and losses

Whenever realized, exchange gains on the Designated Account will be the benefit of Government of Uganda. Similarly, Government of Uganda will meet any realized exchange losses.

